Morningstar

Illumina Inc ILMN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$160.97 −5.24 (3.15%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle

Julie Utterback

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.

Read Full Report

Price vs Fair Value

View History
ILMN is trading at a 537% premium.
Price
$160.97
Fair Value
$428.00
Uncertainty
Dxk
1-Star Price
$313.91
5-Star Price
$31.00
Economic Moat
Cfbttw
Capital Allocation
Dhhcdry

Bulls Say, Bears Say

Bulls

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth opportunities for Illumina even without owning all of Grail.

Bears

Disruptive technology risks could threaten Illumina's industry-leading sequencing platform, leading to market share losses.

Show More

News

View All

Trading Information

Previous Close Price
$166.21
Day Range
$159.34–168.00
52-Week Range
$85.77–177.22
Bid/Ask
$158.00 / $169.15
Shares Outstanding
151.30M
Market Cap
$24.35B
Volume/Avg
1M / 2M

Key Statistics

Price/Earnings (Normalized)
33.04
Price/Sales
5.85
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
3.05%

Company Profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
8,650
Website
https://www.illumina.com

Competitors

Valuation

View More
Metric
ILMN
TMO
Price/Earnings (Normalized)
 33.0420.27
Price/Book Value
 9.443.36
Price/Sales
 5.853.91
Price/Cash Flow
 20.1318.14
Price/Earnings
ILMN
TMO

Financial Strength

Metric
ILMN
TMO
Quick Ratio
 1.210.97
Current Ratio
 1.751.53
Interest Coverage
 11.205.35
Quick Ratio
ILMN
TMO

Profitability

Metric
ILMN
TMO
Return on Assets (Normalized)
 13.27%8.27%
Return on Equity (Normalized)
 33.85%17.01%
Return on Invested Capital (Normalized)
 17.57%10.28%
Return on Assets
ILMN
TMO

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
GbmnhnnynVpr$174B
 Danaher Corp
DHR
XzdslrfsvYmxtb$127B
 IDEXX Laboratories Inc
IDXX
QhdhypgmGmxf$44B
 Agilent Technologies Inc
A
PmrjzphfZfysk$37B
 Waters Corp
WAT
WgygyrlfSqtn$35B
 IQVIA Holdings Inc
IQV
NmyqwbrNrgkcpc$30B
 Mettler-Toledo International Inc
MTD
MlvwrggmzcTplcjnp$23B
 Quest Diagnostics Inc
DGX
LvzfvptNyxdx$22B
 Labcorp Holdings Inc
LH
YqggkjqjymXsfcv$22B

Sponsor Center